An example of such a substance is imatinib (IMA) [42], developed in the second half of the 1990s [43,44] and approved for the treatment of chronic myeloid leukemia as the first representative of protein kinase inhibitors in 2000 [45]. The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.